dc.contributor.author | Lerum, Tøri Vigeland | |
dc.contributor.author | Maltzahn, Niklas | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Trøseid, Marius | |
dc.contributor.author | Nezvalova-Henriksen, Katerina | |
dc.contributor.author | Kåsine, Trine | |
dc.contributor.author | Dyrhol-Riise, Anne Ma | |
dc.contributor.author | Stiksrud, Birgitte | |
dc.contributor.author | Haugli, Mette | |
dc.contributor.author | Blomberg, Bjørn | |
dc.contributor.author | Kittang, Bård Reiakvam | |
dc.contributor.author | Johannessen, Asgeir | |
dc.contributor.author | Hannula, Raisa | |
dc.contributor.author | Aballi, Saad | |
dc.contributor.author | Kildal, Anders Benjamin | |
dc.contributor.author | Eiken, Ragnhild | |
dc.contributor.author | Dahl, Tuva Børresdatter | |
dc.contributor.author | Lund-Johansen, Fridtjof | |
dc.contributor.author | Müller, Fredrik | |
dc.contributor.author | Rivero, Jezabel Rodriguez | |
dc.contributor.author | Meltzer, Carin | |
dc.contributor.author | Einvik, Gunnar | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Olsen, Inge Christoffer | |
dc.contributor.author | Barratt-Due, Andreas | |
dc.contributor.author | Aaløkken, Trond Mogens | |
dc.contributor.author | Skjønsberg, Ole Henning | |
dc.date.accessioned | 2022-01-20T10:17:01Z | |
dc.date.available | 2022-01-20T10:17:01Z | |
dc.date.created | 2021-12-15T12:33:00Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://hdl.handle.net/11250/2838437 | |
dc.description.abstract | The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Nature Research | en_US |
dc.relation.uri | https://www.nature.com/articles/s41598-021-02547-x.pdf | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Persistent pulmonary pathology after COVID‑19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase‑9 | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright The Author(s) 2021 | en_US |
dc.source.articlenumber | 23205 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1038/s41598-021-02547-x | |
dc.identifier.cristin | 1968854 | |
dc.source.journal | Scientific Reports | en_US |
dc.identifier.citation | Scientific Reports. 2021, 11, 23205. | en_US |
dc.source.volume | 11 | en_US |